{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:27:25Z","timestamp":1770895645658,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T00:00:00Z","timestamp":1473811200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00066-016-1041-5","type":"journal-article","created":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T13:19:47Z","timestamp":1473859187000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Hypofractionated radiotherapy for localized prostate cancer","Hypofraktionierte Radiotherapie des lokalisierten Prostatakarzinoms"],"prefix":"10.1007","volume":"193","author":[{"given":"Stefan","family":"H\u00f6cht","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Aebersold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"B\u00f6hmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Flentje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Ganswindt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Sedlmayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Wenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Zips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,14]]},"reference":[{"key":"1041_CR1","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00066-015-0843-1","volume":"191","author":"W Budach","year":"2015","unstructured":"Budach W, Matuschek C, Bolke E et\u00a0al (2015) DEGRO practical guidelines for radiotherapy of breast cancer V: therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases. Strahlenther Onkol 191:623\u2013633","journal-title":"Strahlenther Onkol"},{"key":"1041_CR2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","volume":"362","author":"TJ Whelan","year":"2010","unstructured":"Whelan TJ, Pignol JP, Levine MN et al (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362:513\u2013520","journal-title":"N Engl J Med"},{"key":"1041_CR3","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","volume":"14","author":"JS Haviland","year":"2013","unstructured":"Haviland JS, Owen JR, Dewar JA et al (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14:1086\u20131094","journal-title":"Lancet Oncol"},{"key":"1041_CR4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2014.08.009","volume":"68","author":"BF Koontz","year":"2015","unstructured":"Koontz BF, Bossi A, Cozzarini C et\u00a0al (2015) A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol 68:683\u2013691","journal-title":"Eur Urol"},{"key":"1041_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2010.06.001","volume":"96","author":"M Baumann","year":"2010","unstructured":"Baumann M, H\u00f6lscher T, Denham J (2010) Fractionation in prostate cancer \u2013 is it time after all? Radiother Oncol 96:1\u20135","journal-title":"Radiother Oncol"},{"key":"1041_CR6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.radonc.2010.03.020","volume":"96","author":"HD Thames","year":"2010","unstructured":"Thames HD, Kuban D, Levy LB et\u00a0al (2010) The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol 96:6\u201312","journal-title":"Radiother Oncol"},{"key":"1041_CR7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijrobp.2012.03.004","volume":"85","author":"IR Vogelius","year":"2013","unstructured":"Vogelius IR, Bentzen SM (2013) Meta-analysis of the alpha\/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys 85:89\u201394","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR8","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ijrobp.2005.07.970","volume":"64","author":"A Pollack","year":"2006","unstructured":"Pollack A, Hanlon AL, Horwitz EM et\u00a0al (2006) Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64:518\u2013526","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.radonc.2006.05.012","volume":"79","author":"D Boehmer","year":"2006","unstructured":"Boehmer D, Maingon P, Poortmans P et\u00a0al (2006) Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol 79:259\u2013269","journal-title":"Radiother Oncol"},{"key":"1041_CR10","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.ijrobp.2011.10.009","volume":"83","author":"H Deutschmann","year":"2012","unstructured":"Deutschmann H, Kametriser G, Steininger P et al (2012) First clinical release of an online, adaptive, aperture-based image-guided radiotherapy strategy in intensity-modulated radiotherapy to correct for inter- and intrafractional rotations of the prostate. Int J Radiat Oncol Biol Phys 83:1624\u20131632","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR11","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB et al (2016) Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 34:2325\u20132332","journal-title":"J Clin Oncol"},{"key":"1041_CR12","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1200\/JCO.2005.06.153","volume":"23","author":"H Lukka","year":"2005","unstructured":"Lukka H, Hayter C, Julian JA et\u00a0al (2005) Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J\u00a0Clin Oncol 23:6132\u20136138","journal-title":"J Clin Oncol"},{"key":"1041_CR13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","volume":"17","author":"S Aluwini","year":"2016","unstructured":"Aluwini S, Pos F, Schimmel E et al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol 17:464\u2013474","journal-title":"Lancet Oncol"},{"key":"1041_CR14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","volume":"16","author":"S Aluwini","year":"2015","unstructured":"Aluwini S, Pos F, Schimmel E et al (2015) Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 16:274\u2013283","journal-title":"Lancet Oncol"},{"issue":"8","key":"1041_CR15","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/s1470-2045(16)30070-5","volume":"17","author":"L Incrocci","year":"2016","unstructured":"Incrocci L, Wortel RC, Alemayehu WG et al (2016) Hypofractionated radiotherapy for patients with localised prostate cancer (HYPRO): Final efficacy results from a randomised, multicentre, open-label, phase3 trial. Lancet Oncol 17(8):1061\u20131069. doi: 10.1016\/s1470-2045(16)30070-5","journal-title":"Lancet Oncol"},{"key":"1041_CR16","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5\u2011year outcomes of the randomised, non-inferiority, phase3 CHHIP trial. Lancet Oncol 17:1047\u20131060","journal-title":"Lancet Oncol"},{"key":"1041_CR17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(11)70293-5","volume":"13","author":"D Dearnaley","year":"2012","unstructured":"Dearnaley D, Syndikus I, Sumo G et al (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13:43\u201354","journal-title":"Lancet Oncol"},{"key":"1041_CR18","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","volume":"31","author":"A Pollack","year":"2013","unstructured":"Pollack A, Walker G, Horwitz EM et al (2013) Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31:3860\u20133868","journal-title":"J Clin Oncol"},{"key":"1041_CR19","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.ijrobp.2015.07.086","volume":"93","author":"T Shaikh","year":"2015","unstructured":"Shaikh T, Li T, Johnson ME et al (2015) Long-term patient reported outcomes from a phase 3 randomized prospective trial of conventional versus hypofractionated IMRT radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 93:S34\u2013S36","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR20","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ijrobp.2010.07.1984","volume":"81","author":"EE Yeoh","year":"2011","unstructured":"Yeoh EE, Botten RJ, Butters J et\u00a0al (2011) Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 81:1271\u20131278","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR21","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.ijrobp.2010.07.170","volume":"78","author":"D Kuban","year":"2010","unstructured":"Kuban D, Nogueras-Gonzalez GM, Hamblin L et al (2010) Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys 78:S58\u201359","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR22","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ijrobp.2014.01.015","volume":"88","author":"KE Hoffman","year":"2014","unstructured":"Hoffman KE, Voong KR, Pugh TJ et al (2014) Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys 88:1074\u20131084","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR23","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ijrobp.2009.12.045","volume":"79","author":"G Arcangeli","year":"2011","unstructured":"Arcangeli G, Fowler J, Gomellini S et al (2011) Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 79:1013\u20131021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2009.07.1691","volume":"78","author":"G Arcangeli","year":"2010","unstructured":"Arcangeli G, Saracino B, Gomellini S et al (2010) A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 78:11\u201318","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR25","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2012.02.049","volume":"84","author":"S Arcangeli","year":"2012","unstructured":"Arcangeli S, Strigari L, Gomellini S et al (2012) Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84:1172\u20131178","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR26","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.ijrobp.2006.06.005","volume":"66","author":"EE Yeoh","year":"2006","unstructured":"Yeoh EE, Holloway RH, Fraser RJ et\u00a0al (2006) Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 66:1072\u20131083","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR27","first-page":"3049","volume":"35","author":"F Tramacere","year":"2015","unstructured":"Tramacere F, Arcangeli S, Pignatelli A et al (2015) Hypofractionated dose escalated 3D conformal radiotherapy for prostate cancer: outcomes from a mono-institutional phase II study. Anticancer Res 35:3049\u20133054","journal-title":"Anticancer Res"},{"key":"1041_CR28","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.urology.2014.07.060","volume":"84","author":"AM McDonald","year":"2014","unstructured":"McDonald AM, Baker CB, Shekar K et al (2014) Reduced radiation tolerance of penile structures associated with dose-escalated hypofractionated prostate radiotherapy. Urology 84:1383\u20131387","journal-title":"Urology"},{"key":"1041_CR29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00066-015-0928-x","volume":"192","author":"PM Putora","year":"2016","unstructured":"Putora PM, Engeler D, Haile SR et\u00a0al (2016) Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients. Strahlenther Onkol 192:182\u2013189","journal-title":"Strahlenther Onkol"},{"key":"1041_CR30","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.eururo.2014.06.012","volume":"66","author":"C Cozzarini","year":"2014","unstructured":"Cozzarini C, Fiorino C, Deantoni C et al (2014) Higher-than-expected severe (Grade 3\u20134) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur Urol 66:1024\u20131030","journal-title":"Eur Urol"},{"key":"1041_CR31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijrobp.2015.11.025","volume":"94","author":"SL Lewis","year":"2016","unstructured":"Lewis SL, Patel P, Song H et\u00a0al (2016) Image guided hypofractionated postprostatectomy intensity modulated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 94:605\u2013611","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR32","doi-asserted-by":"crossref","first-page":"A5003","DOI":"10.1200\/JCO.2016.34.15_suppl.5003","volume":"34","author":"CN Catton","year":"2016","unstructured":"Catton CN, Lukka H, Julian JA et\u00a0al (2016) A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. J\u00a0Clin Oncol 34:A5003","journal-title":"J Clin Oncol"},{"key":"1041_CR33","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","volume":"82","author":"CR King","year":"2012","unstructured":"King CR, Brooks JD, Gill Presti HJC Jr. (2012) Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 82:877\u2013882","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/153303460900800509","volume":"8","author":"JL Friedland","year":"2009","unstructured":"Friedland JL, Freeman DE, Masterson-McGary ME et al (2009) Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 8:387\u2013392","journal-title":"Technol Cancer Res Treat"},{"key":"1041_CR35","first-page":"301","volume":"4","author":"AJ Katz","year":"2014","unstructured":"Katz AJ, Kang J (2014) Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7\u2011year study. Front Oncol 4:301","journal-title":"Front Oncol"},{"key":"1041_CR36","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","volume":"29","author":"TP Boike","year":"2011","unstructured":"Boike TP, Lotan Y, Cho LC et al (2011) Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 29:2020\u20132026","journal-title":"J Clin Oncol"},{"key":"1041_CR37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.radonc.2013.03.022","volume":"107","author":"A Loblaw","year":"2013","unstructured":"Loblaw A, Cheung P, D\u2019Alimonte L et\u00a0al (2013) Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol 107:153\u2013158","journal-title":"Radiother Oncol"},{"key":"1041_CR38","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","volume":"28","author":"AL Zietman","year":"2010","unstructured":"Zietman AL, Bae K, Slater JD et al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group\/american college of radiology 95-09. J Clin Oncol 28:1106\u20131111","journal-title":"J Clin Oncol"},{"key":"1041_CR39","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S1569-9056(13)62393-3","volume":"12","author":"S Aluwini","year":"2013","unstructured":"Aluwini S, Beltramo G, Van Rooij P et al (2013) Stereotactic body radiotherapy with four fractions for low- and intermediate-risk prostate cancer: acute and late toxicity. Eur Urol 12:156","journal-title":"Eur Urol"},{"key":"1041_CR40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2490-13-49","volume":"13","author":"G Bolzicco","year":"2013","unstructured":"Bolzicco G, Favretto MS, Satariano N et al (2013) A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol 13:49","journal-title":"BMC Urol"},{"key":"1041_CR41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1748-717X-8-58","volume":"8","author":"LN Chen","year":"2013","unstructured":"Chen LN, Suy S, Uhm S et\u00a0al (2013) Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol 8:58","journal-title":"Radiat Oncol"},{"key":"1041_CR42","first-page":"44","volume":"44","author":"L D\u2019Alimonte","year":"2013","unstructured":"D\u2019Alimonte L, Loblaw A, Cheung P et\u00a0al (2013) Long term outcomes of a novel five fraction hypofractionated protocol for low risk prostate cancer. J\u00a0Med Imaging Radiat Sci 44:44\u201358","journal-title":"J Med Imaging Radiat Sci"},{"key":"1041_CR43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fonc.2014.00369","volume":"4","author":"D Freeman","year":"2015","unstructured":"Freeman D, Dickerson G, Perman M (2015) Multi-institutional registry for prostate cancer radiosurgery: a prospective observational clinical trial. Front Oncol 4:369","journal-title":"Front Oncol"},{"key":"1041_CR44","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.ijrobp.2012.07.384","volume":"84","author":"DB Fuller","year":"2012","unstructured":"Fuller DB, Mardirossian G, Wong D et al (2012) Prospective evaluation of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: emulating high-dose-rate brachytherapy dose distribution. Int J Radiat Oncol Biol Phys 84:S149","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1041_CR45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ijrobp.2015.10.046","volume":"94","author":"H Lukka","year":"2016","unstructured":"Lukka H, Stephanie P, Bruner D et al (2016) Patient-reported outcomes in NRG oncology\/RTOG 0938, a randomized phase 2 study evaluating 2 ultrahypofractionated regimens (UHRs) for prostate cancer. Int J Radiat Oncol Biol Phys 94(1):2","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR46","doi-asserted-by":"crossref","first-page":"S326","DOI":"10.1016\/j.ijrobp.2009.07.747","volume":"75","author":"CA Mantz","year":"2009","unstructured":"Mantz CA, Fernandez E, Zucker Harrison IS (2009) A phase II trial of Varian trilogy-based SBRT for low-risk prostate cancer: report of early toxicity and disease control outcomes. Int J Radiat Oncol Biol Phys 75:S326","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR47","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1016\/j.ijrobp.2012.07.382","volume":"84","author":"R Meier","year":"2012","unstructured":"Meier R, Kaplan I, Beckman A et al (2012) Stereotactic body radiation therapy for intermediate-risk organ-confined prostate cancer: interim toxicity and quality of life outcomes from a multi-institutional study. Int J Radiat Oncol Biol Phys 84:S148","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR48","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.ijrobp.2013.06.069","volume":"87","author":"R Meier","year":"2013","unstructured":"Meier R, Kaplan I, Beckman A et al (2013) Patient-reported quality of life outcomes in intermediate-risk prostate cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 87:S25","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR49","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1748-717X-6-112","volume":"6","author":"C Menkarios","year":"2011","unstructured":"Menkarios C, Vigneault E, Brochet N et al (2011) Toxicity report of once weekly radiation therapy for low-risk prostate adenocarcinoma: preliminary results of a phase I\/II trial. Radiat Oncol 6:112","journal-title":"Radiat Oncol"},{"key":"1041_CR50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13566-012-0067-2","volume":"2","author":"C Oliai","year":"2013","unstructured":"Oliai C, Lanciano R, Sprandio B et\u00a0al (2013) Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J\u00a0Radiat Oncol 2:63\u201370","journal-title":"J Radiat Oncol"},{"key":"1041_CR51","first-page":"S46","volume":"96","author":"H Quon","year":"2010","unstructured":"Quon H, Cheung P, Cesta A et al (2010) Prospective study of extreme hypofractionated radiotherapy (35GY in five fractions) for low-risk prostate cancer: toxicity results. Radiother Oncol 96:S46","journal-title":"Radiother Oncol"},{"key":"1041_CR52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1748-717X-9-148","volume":"9","author":"LN Chen","year":"2014","unstructured":"Chen LN, Suy S, Wang H et al (2014) Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat Oncol 9:148","journal-title":"Radiat Oncol"},{"key":"1041_CR53","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1200\/JCO.2013.53.8652","volume":"32","author":"JB Yu","year":"2014","unstructured":"Yu JB, Cramer LD, Herrin J et al (2014) Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol 32:1195\u20131201","journal-title":"J Clin Oncol"},{"key":"1041_CR54","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.rpor.2014.02.006","volume":"19","author":"K Behrendt","year":"2014","unstructured":"Behrendt K, Nowicka E, Gawkowska-Suwinska M et al (2014) Early closure of phase II prospective study on acute and late tolerance of hypofractionated radiotherapy in low-risk prostate cancer patients. Rep Pract Oncol Radiother 19:337\u2013342","journal-title":"Rep Pract Oncol Radiother"},{"key":"1041_CR55","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ijrobp.2014.03.012","volume":"89","author":"DW Kim","year":"2014","unstructured":"Kim DW, Cho LC, Straka C et al (2014) Predictors of rectal tolerance observed in a dose-escalated phase 1\u20132 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 89:509\u2013517","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR56","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fonc.2014.00290","volume":"4","author":"Z Rana","year":"2014","unstructured":"Rana Z, Cyr RA, Chen LN et\u00a0al (2014) Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer. Front Oncol 4:290","journal-title":"Front Oncol"},{"key":"1041_CR57","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00066-015-0914-3","volume":"191","author":"M Simon","year":"2015","unstructured":"Simon M, Habeck M, B\u00fcttner D et\u00a0al (2015) Approval procedures for clinical trials in the field of radiation oncology. Strahlenther Onkol 191:909\u2013920","journal-title":"Strahlenther Onkol"},{"key":"1041_CR58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.radonc.2006.08.015","volume":"81","author":"H Ishikawa","year":"2006","unstructured":"Ishikawa H, Tsuji H, Kamada T et\u00a0al (2006) Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother Oncol 81:57\u201364","journal-title":"Radiother Oncol"},{"key":"1041_CR59","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ijrobp.2012.01.072","volume":"84","author":"T Okada","year":"2012","unstructured":"Okada T, Tsuji H, Kamada T et\u00a0al (2012) Carbon ion radiotherapy in advanced hypofractionated regimens for prostate cancer: from 20 to 16 fractions. Int J Radiat Oncol Biol Phys 84:968\u2013972","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR60","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1038\/bjc.2014.191","volume":"110","author":"T Nomiya","year":"2014","unstructured":"Nomiya T, Tsuji H, Maruyama K et\u00a0al (2014) Phase I\/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3\u00a0weeks. Br J Cancer 110:2389\u20132395","journal-title":"Br J Cancer"},{"key":"1041_CR61","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ijrobp.2013.11.007","volume":"88","author":"NP Mendenhall","year":"2014","unstructured":"Mendenhall NP, Hoppe BS, Nichols RC et al (2014) Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys 88:596\u2013602","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1041_CR62","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000241","author":"CE Vargas","year":"2015","unstructured":"Vargas CE, Hartsell WF, Dunn M et al (2015) Hypofractionated versus standard fractionated proton-beam therapy for low-risk prostate cancer: interim results of a randomized trial PCG GU 002. Am J Clin Oncol. doi: 10.1097\/COC.0000000000000241","journal-title":"Am J Clin Oncol"},{"key":"1041_CR63","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1471-2407-14-202","volume":"14","author":"G Habl","year":"2014","unstructured":"Habl G, Hatiboglu G, Edler L et\u00a0al (2014) Ion Prostate Irradiation (IPI) \u2013 a pilot study to establish the safety and feasibility of primary hypofractionated irradiation of the prostate with protons and carbon ions in a raster scan technique. BMC Cancer 14:202","journal-title":"BMC Cancer"}],"updated-by":[{"DOI":"10.1007\/s00066-016-1054-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T00:00:00Z","timestamp":1476662400000}}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-016-1041-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-016-1041-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-016-1041-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T13:32:32Z","timestamp":1568381552000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-016-1041-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,14]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["1041"],"URL":"https:\/\/doi.org\/10.1007\/s00066-016-1041-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00066-016-1054-0","asserted-by":"object"}]},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,14]]}}}